NASDAQ$AKBA
Akebia Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Akebia reported financial results for the second quarter ended June 30, 2024, and recent business highlights.
Akebia Therapeutics reported total revenues of $43.6 million and a net loss of $8.6 million for the second quarter of 2024. The company is focused on the commercial launch of Vafseo and contracting Auryxia through dialysis organizations.
- Vafseo market availability is on track for January 2025.
- TDAPA application submission and WAC pricing announcement for Vafseo were completed.
- Auryxia net product revenues for the second quarter of 2024 were $41.2 million.
- Akebia regained full rights to sell Vafseo in the U.S.
Headline financials
Revenue & EPS history
Akebia · Revenue · Quarterly
$43.6M
Revenue by segment
Akebia · $40.1M total across 2 segments · Q1 2023
- Auryxia$34.8M-15.9%86.8%
- License & other revenue$5.3M-73.8%13.2%
Forward guidance
Akebia expects Auryxia full year 2024 net product revenues to be in line with 2023 Auryxia net product revenue levels and anticipates phosphate binders will be added to the Centers for Medicare & Medicaid Services bundled payment for dialysis care in January 2025. Akebia expects its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including the U.S. Vafseo launch, for at least two years.
Tailwinds
- Vafseo global launch activities are underway.
- Akebia is actively contracting Auryxia through dialysis organizations for 2025.
- Akebia expects phosphate binders to be added to the Centers for Medicare & Medicaid Services bundled payment for dialysis care in January 2025.
- Akebia expects existing cash resources and cash from operations will be sufficient to fund its current operating plan for at least two years.
- Akebia expects to have HCPCS codes assigned in October 2024 and TDAPA designation by January 1, 2025.
Headwinds
- Vafseo sales in dialysis will be under contracts that include an off-invoice discount as well as volume-based tier discounts off the WAC price.
- Akebia is exposed to risks associated with the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to, Auryxia and Vafseo, including estimates regarding the potential market opportunity
- Akebia is exposed to risks associated with the competitive landscape for Auryxia and Vafseo, including potential generic entrants
- Akebia is exposed to risks associated with decisions made by health authorities, such as the FDA, with respect to regulatory filings
- Akebia is exposed to risks associated with the potential therapeutic benefits, safety profile, and effectiveness of Vafseo
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-2.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
41%
19 / 46 earnings
Positive
+34.4%
Q1 2020
Best reaction
-22.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -20.3% | -20.3% | -36.7% | |
| Q4 2025 | +9.9% | +0.8% | +10.7% | |
| Q3 2025 | -18.4% | -18.1% | -20.1% | |
| Q1 2025 | +6.6% | +0.8% | +61.4% | |
| Q4 2024 | -12.4% | +32.1% | -14.5% | |
| Q3 2024 | -3.0% | -2.5% | +2.5% | |
| Q2 2024 | +0.0% | +20.7% | +21.6% | |
| Q1 2024 | -13.6% | -12.1% | -24.3% | |
| Q4 2023 | +20.6% | +29.8% | +3.5% | |
| Q3 2023 | -16.5% | -15.3% | +3.7% | |
| Q2 2023 | +10.4% | +12.0% | -5.6% | |
| Q1 2023 | -3.7% | +3.7% | +17.4% | |
| Q4 2022 | -22.4% | -33.7% | -47.6% | |
| Q3 2022 | +1.9% | +2.6% | +9.0% | |
| Q2 2022 | +1.0% | +3.6% | -2.8% | |
| Q1 2022 | +11.2% | +16.6% | +15.6% | |
| Q4 2021 | +13.4% | +12.0% | -66.8% | |
| Q3 2021 | -12.3% | -14.4% | -24.6% | |
| Q2 2021 | +10.5% | +6.5% | +22.2% | |
| Q1 2021 | +2.6% | +10.6% | +17.9% | |
| Q4 2020 | -19.2% | -17.5% | -26.2% | |
| Q3 2020 | -7.4% | +0.8% | +19.8% | |
| Q2 2020 | -6.4% | -4.1% | -75.9% | |
| Q1 2020 | +34.4% | +38.3% | +40.6% | |
| Q4 2019 | -13.8% | -27.0% | -13.0% | |
| Q3 2019 | -9.6% | -8.2% | +73.5% | |
| Q2 2019 | +20.5% | +22.4% | +11.2% | |
| Q1 2019 | +1.5% | -0.7% | -26.8% | |
| Q4 2018 | -0.9% | +2.7% | -15.3% | |
| Q3 2018 | +10.3% | -4.2% | +5.0% | |
| Q2 2018 | -18.1% | -22.1% | -20.8% | |
| Q1 2018 | +0.7% | +11.0% | +10.5% | |
| Q4 2017 | -10.6% | -12.6% | -28.9% | |
| Q3 2017 | -12.6% | -12.8% | -8.5% | |
| Q2 2017 | +6.8% | +9.4% | +26.0% | |
| Q1 2017 | -2.3% | +2.2% | +8.2% | |
| Q4 2016 | -12.6% | -9.3% | -11.1% | |
| Q3 2016 | +10.6% | +14.1% | +9.9% | |
| Q2 2016 | -9.6% | -7.4% | -3.8% | |
| Q1 2016 | -8.8% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +3.3% | — | — | |
| Q3 2014 | -3.2% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro